Hypercoagulable states are a group of conditions associated with increased predisposition to thromboembolic events. Most of the inherited abnormalities recognized to date are associated with venous thromboembolism (VTEI rather than arterial thrombosis. The wellrecognized inherited hypercoagulable states are the deficiencies of antithrombin, protein e and protein S, and the resistance to APe (factor V Leiden). These entities represent aberrations in the natural anticoagulant systems that exist in plasma. Other causes of inherited thrombophilia include abnormalities in the proteins of the fibrinolytic system, dysfibrinogenemias, deficiency of heparin cofactor II, abnormal thrombomodulin, elevated levels of histidine-rich glycoprotein, and the recently described variation in the prothrombin gene. One entity that has become firmly established as a predisposing factor for recurrent VTE is hyperhomocysteinemia. About half of VTE episodes in patients with inherited thrombophilias occur in relation to events that are generally recognized as predisposing states, such as surgery, pregnancy (particularly puerperium) and immobilization. In this review, the risks of VTE associated with inherited risk factors are discussed, and guidelines for the diagnosis and management are presented.
Introduction
Hypercoagulable states are a group of conditions associated with increased predisposition to thromboembolic events. Most of the inherited abnormalities recognized to date are associated with venous thrombosis rather than arterial thrombosis. With the description by Egeberg I in 1965 of a family with antithrombin (AT) deficiency and frequent occurrence of thrombotic episodes, it became firmly established that an increased predisposition to venous thromboembolism (VTE) may be familial and associated with alterations in specific plasma proteins. In the last 20 years other plasma protein deficiencies have been described, such as those of protein C (PC) and protein S (PS), which also lead to such a predisposition. Although deficiencies of AT, PC and PS have now been recognized for some time, it is clear that they occur in a small proportion of patients considered to have an inherited hypercoagulable state or recurrent VTE. In 1993, Dahlback et al 2 and Griffin et aI' reponed that certain individuals with recurrent VTE responded poorly to the anticoagulant action of activated protein C (APC). This entity, termed resistance to APC. results from a specific point mutation in the factor V gene,":" and has become the most frequently identified inherited abnormality in patients with recurrent VTE. Aside from these inherited abnormalities, a number of acquired states, such as antiphospholipid antibody syndrome, lupus anticoagulants, postoperative states, myeloproliferative diseases, and prolonged immobilization also predispose to VTE. This article will Division of Hematology and Thromboembolic Diseases and thc Sol Sherry Thrombosis Research Center. Temple University School of Medicine. Philadelphia. PA. USA abnormalities leading to the increase in plasma homocysteine levels may be diverse and either inherited or acquired.
Molecular abnormalities leading to hypercoagulable states
Antithrombin deficiency Antithrombin, also known as antithrombin III and heparin cofactor, is a single chain glycoprotein (molecular weight 60 kD) that is synthesized in the hepatocyte and belongs to the superfamily of the serine protease inhibitors (serpins). It has a half-life of 65 h and a plasma concentration of 2.5 fLM. AT inactivates thrombin and other serine proteases including factors Xa, IXa, XIa, XIIa and kallikrein by forming an irreversible I: I molar complex involving its reactive site at Arg393 and Ser394 and the active site of the protease. This inhibition is accelerated at least 1000fold by heparin or other proteoglycans such as heparan sulfate. The interaction with heparin results in a conformational change and formation of a ternary complex of heparin-ATprotease that brings the reactive site of AT into close contact with the active site of the protease.
AT deficiency is inherited in an autosomal dominant pattern with the majority of individuals demonstrating heterozygosity. Normal plasma AT levels range from about 70% to 120% and deficient individuals generally present with about -50% of the normal level. In general, two types of AT deficiency are recognized.' Type 1 AT deficiency, the most common type, is characterized by a concordant reduction in the levels of both AT antigen and activity in plasma. There are 101 cases of identified point mutations (including small deletions and insertions), and 12 partial (defined arbitrarily at > 30 bp) and whole gene deletions.
Type II AT deficiency is characterized by normal antigen levels with a reduction in functional levels secondary to an abnormal molecule. This is further stratified according to the molecular defect. Type II reacti ve site (RS) is identified by a defect in the reactive site of the AT molecule. Twelve different missense mutations (55 cases) have been reported in type II RS defects, although not all phenotypes result in the failure to inhibit proteases. Antithrombin with a defect in the heparin binding site (HBS) is defined as a type II HBS. There have been 12 distinct mutations and 70 cases reported of type II HBS. Type II PE (pleiotropic effect) is characterized by multiple functional defects. Eleven distinct mutations and 18 cases have been reported with a type II PE defect. Patients with heterozygous defects in HBS appear to have lower risk of thrombosis compared to other type II variants." Only individuals who are homozygous for type II HBS or double heterozygotes appear to be at risk for thromboembolic events.
Abnormalities in protein C system The principal proteins of this system are PC (molecular weight 62 kD) and PS (molecular weight 69 kD), two vitamin K-dependent proteins that are synthesized in the liver, and thrombomodulin, an endothelial protein. PC and PS have half-lives of 6--8 h and 42 h, respectively. PC is activated by thrombin to APC by a mechanism requiring thrombomodulin. Thrombin binds to thrombomodulin on the endothelial surface and activates PC to APC. In the presence of its cofactor PS. APC inactivates factor Va and Vascular Medicine 1997: 2: 313-320 factor VIlla, thereby constituting an important natural anticoagulant mechanism controlling further thrombin generation. APC inactivates factor Va through initial cleavage at Arg506 and subsequently at Arg306 and Arg679. 9 Most (60-65%) of PS circulates in plasma bound to complement C4b-binding protein and the complexed PS is not active as a cofactor for PC.
PC deficiency is a heterogeneous disorder 10. I 1 with over 160 different mutations documented. Based on laboratory findings, two phenotypes can be recognized: type I where both PC antigen and activity in plasma are decreased to the same extent, and type II where the activity is disproportionately lower than the antigen. A large number (> 70) of mutations have been described in PS deficiency. I I Based on the observations that PS exists in plasma in two molecular forms, i.e., free PS and C4b-binding protein-bound PS, and that only the free PS has APC cofactor activity, there are three types of PS deficiency that have been defined. I I Type I deficiency is characterized by low total and free PS antigen levels in plasma, and type II deficiency by normal free PS and low APC cofactor activity. In type III deficiency, free PS levels are low but the total PS levels are normal. Recently, a point mutation in the thrornbomodulin gene has been documented in a patient with thromboembolic disease."
Resistance to activated protein C and factor V Leiden A landmark study in the search for inherited mechanisms leading to recurrent VTE is the documentation that some individuals are resistant to the anticoagulant effect of APC. D A single point mutation (G to A transition of nucleotide 1691) in exon 10 of factor V gene leads to the substitution of arginine 506 by glutamine (factor V Leiden) and results in a factor V molecule that is resistant to cleavage by APC 4 .5 but has normal procoagulant activity. This mutation occurs in over 90% of patients investigated with APC resistance.
Abnormalities in the fibrinolytic system
The association of inherited defects in the plasma fibrinolytic system with predisposition to VTE is less well established than for the entities described earlier. 13 In theory. decreased or abnormal plasminogen, decreased tissue plasminogen activator (t-PA), or increased plasminogen activator inhibitor (PAl-I) levels in plasma may predispose to thrombosis. It has been suggested that venous thrombosis may be associated with impaired fibrinolytic activity." In family studies of inherited deficiency of plasminogen, only the proband has been noted to have thrombosis as compared to other affected family members. 15 In another study, In heterozygous plasminogen deficiency was associated with increased risk of thrombosis.
Dysfibrinogenemia
Abnormal fibrinogen or dysfibrinogenemia may be characterized clinically by bleeding symptoms (-25%), arterial or venous thrombosis (-20%), or by the absence of associated symptoms (-50lk). 17 The evidence for the association of venous thrombosis with dysfibrinogenemia has been recently reviewed to include 26 cases of familial dystibrinogenemia and thrombosis.!" Of the 187 relatives investigated, 20 out of 99 individuals with dysfibrinogenemia had a history of thrombosis compared with none of 88 subjects without evidence of dysfibrinogenemia. Overall the prevalence of dysfibrinogenemia in patients with a history of venous thrombosis is low « IO/(). IX In most cases. it is transmitted primarily as an autosomal dominant disorder. Mutations have been described in the C-terminal portion of the )I-chain. the N-terminal part of the B~-chain and in the Au-chain. It is unclear why a particular molecular defect leads to thrombosis. In the laboratory, patients with dysfibrinogenemia may be characterized by a prolonged thrombin time. a prolonged reptilase time, and a disparity between functional (clottable) fibrinogen and antigenic fibrinogen levels. Some individuals may present with hypodysfibrinogenemia.
Prothrombin Variant 20210 G to A
A recently described risk factor relates elevated plasma prothrombin levels to increased risk of thrombosis. A G to A transition at nucleotide position 20210 in the 3' untranslated region of the prothrombin gene was found to be associated with increased prothrombin levels and with occurrence of VTE. 6 The variant 20210A allele was found in 18% of selected patients with familial thrombosis. In the Leiden Thrombophilia Study. 2.3% of healthy controls and 6.2% of consecutive patients with thrombosis were carriers of the 202 lOA allele (relative risk 2.8). 6 The relatively high prevalence of the mutant allele in normal subjects may make it an important risk factor to examine in alI future studies.
Hyperhomocysteinemia
Homocysteine is a sulfydryl nondietary amino acid generated within the body solely from the metabolic conversion of methionine.l'v" Its major intracellular metabolic pathways consist of its remethylation to methionine and transulfuration to cysteine. In remethylation. the methyl donor methyltetrahydrofolate is formed from the reduction of methylenetetrahydrofolate by the enzyme methylenetetrahydrofolate reductase (MTHFR). Homocysteine then accepts a methyl group either from methyltetrahydrofolate with vitamin B I2 acting as a cofactor. or from betaine (liver specific) to form methionine. In the transulfuration pathway. homocysteine merges with serine to form cystathionine, a reaction catalyzed by cystathionine~-synthase (CBS) and requiring vitamin B 6 • In concert with a homocysteinespecific cellular export mechanism. these processes regulate homocysteine homeostasis. maintaining negligible intracellular levels and stable plasma levels in the range of 5-16 IJomol/l. Alterations in these mechanisms either by genetic defects in the involved enzymes or acquired deficiency states of the necessary vitamin cofactors result in excess homocysteine being delivered into plasma. exposing vascular tissues and blood cells to deleterious effects.
The spectrum of inherited and acquired disturbances in homocysteine metabolism comprise a continuum from mild to severe in their clinical expression depending on the associated level of hyperhomocysteinemia. The most severe cases of hyperhomocysteinemia are caused by homozygous defects in the genes encoding the enzymes involved in the remethylation or transulfuration reactions. The most commonly encountered form of severe hyperhomocysteinemia (congenital homocystinuria) is homozygous deficiency of cystathionine~-synthase. with an estimated frequency in the general population of I:2(x) 000 to 1:355 000. 20 Yascular Mcdicine 1997: 2: 313--320
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Afflicted individuals may have plasma homocysteine levels as high as 400 urnol/l and suffer severe mental retardation. skeletal abnormalities, ectopic lens and premature vascular disease (arterial and venous). Approximately 5-10% of severe hyperhomocysteinemic patients have inherited defects in the remethylation pathway. such as the homozygous deficiency of methylenetetrahydrofolate reductase. This rare entity is associated with severe neurological defects. premature vascular disease. venous thromboembolism and a poor response to treatrnent.!" Mild to moderate hyperhomocysteinemia may occur in a number of genetic and acquired disease states. These include the heterozygous CBS deficiency. which has an incidence of 0.3-1.4% in the general population'? and the homozygous state for the thermolabile variant of MTHFR that occurs in 1.5-150/( of the general population.
depending on the geographic area studied." In the thermolabile variant. the specific activity of MTHFR at 37°C is reduced by 50%,zz Plasma homocysteine levels are strongly influenced by plasma folate. vitamin B I 2 and vitamin BI> levels. Deficiencies of these nutritional factors are a major cause of mild to moderate hyperhomocysteinemia."
Although multiple studies have linked hyperhomocysteinemia to an increased incidence of arterial disease. the relationship between mildly elevated plasma homocysteine and venous thrombosis has been established only more recently.t":" A high incidence of hyperhomocysteinemia has been observed in young patients with venous thrombosis" as well as in individuals with recurrent venous thrombotic events." In the Leiden Thrombophilia Study," lOCk of patients with a first, objectively confirmed deep venous thrombosis had plasma homocysteine levels above the 95th percentile of the levels in controls; the odds ratio for deep vein thrombosis for patients with levels above the 95th percentile was 2.5. Family studies performed in patients with juvenile thrombosis revealed that the preponderance of index cases had at least one first-degree relative with hypcrhomocysteinemia," reflecting the heritability in most cases. A recent study has demonstrated that the coexistence of congenital homocystinuria and the factor V Leiden significantly increases the thrombotic risk over that of homocystinuria alone."
A number of mechanisms have been invoked to explain the processes by which hyperhomocysreinemia induces vascular disease. Early in vivo studies in baboons demonstrated that high homocysteine levels could induce desquamation of endothelial cells and smooth muscle cell proliferation." High concentrations of homocysteine have been reported to induce a number of effects on endothelial cells in vitro, including inhibition of prostacyclin synthesis, activation of factor V. inhibition of protein C activation and down regulation of thrombomodulin expression. inhibition of t-PA binding and decreased plasminogen activation. decreased production of nitric oxide. induction of tissue factor. and increased platelet adhesion.">·:"'..lO Hyperhomocysteinemia is associated with impaired endotheliumdependent vasodilation in elderly subjects." Homocysteine has also been shown to reduce endothelial levels of glutathione peroxidase. an important defense mechanism against oxidative injury.~''.. lO The diagnosis of hyperhomocysteinemia can be accomplished by measuring fasting plasma levels of total homocysteine (homocysteine and its two disulfide products: cysteine and homocysteine-cysteine) by the sensitive methods of ion-exchange chromatography, gas chromatography-mass spectrometry, or high performance liquid chromatography with electrochemical or fluorescent detection. Homocystinurics with homozygous deficiency of CBS have the highest fasting plasma homocysteine levels, usually greater than 100 umol/l. Patients with heterozygous defects have normal or borderline high levels of fasting homocysteine, and use of the oral methionine loading test may improve the distinction." Another method for recognition of the heterozygous state is to measure the CBS activity in cultured skin fibroblasts." In addition. molecular probes are now available for detecting the different mutations in the genes encoding for CBS and MTHFR.
Other abnormalities
A number of other entities have been described in patients with thrombophilia, but evidence for their associations with VTE is not as well established. High plasma levels of histidine-rich glycoprotein (HRG), a protein that complexes with plasma plasminogen thereby reducing free plasminogen concentration.P:" and a deficiency of heparin cofactor II have been reported in some families with thrombophilia. 34.35 Another entity linked to recurrent venous thrombosis is factor XII deficiency.v-" A potential mechanism for this is the impaired activation of the fibrinolytic system observed in factor XII-deficient individuals."
Clinical features of inherited hypercoagulable states
Most patients with inherited hypercoagulable states are heterozygous and patients with aberrations in the natural anticoagulant systems share common features. The clinical events are predominantly venous (deep vein thrombosis. pulmonary embolism) with little evidence that deficiencies of AT, PC, PS or factor V Leiden increase the risk of arterial rhrombosis.t":" Venous thrombosis may occur in unusual sites such as mesenteric or cerebral veins. In general, 60-80% of patients with heterozygous deficiency develop an episode of VTE by the age of 40-45 years 4 0 .4 1 with a recurrence in approximately half of the patients. About half of VTE episodes in these patients occur in relation to events that are generally recognized as predisposing states such as surgery. pregnancy (particularly puerperium) and immobilization. Use of oral contraceptives is associated with a markedly enhanced risk of VTE. 4 2 .4 3 Homozygous AT deficiency appears to be incompatible with life. However. heterozygous deficiency is associated with normal survival. with a low risk of fatal thromboembolic events.t' Patients with homozygous PC or PS deficiency may develop purpura fulminans at birth or soon after; this is characterized by extensive skin necrosis due to thrombosis of small vessels. In general. the risk of VTE is substantially higher in homozygous deficiencies of PC and PS than in heterozygotes. Individuals homozygous for APC resistance have an l l-fold higher risk compared to heterozygotes and an 80-fold increase relative to normal individuals.45
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Prevalence of various deficiencies
Hereditary resistance to APC or factor V Leiden is by far the commonest of all the plasma protein abnormalities resulting in a hypercoagulable state. Resistance to APC or factor V Leiden has been estimated to occur in 3-7% of Caucasians.'>" The homozygous state has been estimated to occur in I in 5000. 4 5 In studies in blood donors. the prevalence of protein C deficiency has been found to be I in 250-500•./ 8 .4 9 and I in 5000 for type I AT deficiency.?" In patients with venous thromboembolic events. the prevalence of PC. PS and AT deficiencies is 5-10% each 5 1 .-53 and that of APC resistance is up to -50%;1 but these studies possibly overestimate the prevalence because of a selection bias. In contrast. the prevalence rates have been consistently lower in studies where consecutive patients with objectively documented deep vein thrombosis were assessed. In these studies. a total of only 5-6% of patients had any of the protein deficiencies (PC, PS or AT);S4.55 20% of the patients had APC resistance." APC resistance is by far the most important abnormality encountered in patients with VTE. One entity highly relevant to this discussion is the recently described polymorphism in the prothrombin gene (202 lOA). which has been noted in 6.2% of consecutive patients with thrombosis and 2.3% of healthy controls." In a second sample of 600 healthy men from Leiden, this allele was found in 1.2%.56 If these findings are confirmed. the factor II 20210A mutation may, indeed. become a risk factor second only to factor V Leiden.
Simultaneous occurrence of multiple gene defects or combinations of genetic and acquired factors predisposing to thrombosis
Because of the marked differences in the clinical thrombotic manifestations observed among heterozygotes for the same protein deficiency. it has been proposed that inherited predisposition to thrombosis may result from simultaneous occurrence of mutations in two or more genes that encode for proteins involved in coagulation." This concept can be easily extended to involve interaction of genetic and acquired factors. For example, 50% of all thrombotic events in patients with deficiencies of PC, PS. AT or factor V Leiden occur in the context of another recognized high risk state such as surgery or pregnancy. Patients with factor V Leiden on oral contraceptives have a remarkable increase in the risk of VTE over that of factor V Leiden alone." There are several reports of the co-existence of more than one inherited predisposing factor deficiency in patients with VTE. This is not entirely unexpected given the relatively high prevalence of FV Leiden. A combination of PC deficiency and APe resistance confer a higher risk for VTE than either alone." Similar interactions have been reported with respect to segregation of defects involving factor V Leiden and deficiencies of AT or PS58-61 or hyperhomocysteinemia.~7 These studies emphasize the need to consider the existence of multiple gene defects in the same family. and different abnormalities among the various members to explain striking disparities in the clinical symptoms.
Risk of thrombosis in various disorders
Information on the risk of thrombosis in various groups of patients has emerged from cross-sectional studies of a~fec ted families. although the estimates are often compromised by selection bias and because in some o~the older~tud.ies diagnosis of VTE was not~llways e.stabh,shed~y ob~ectlve tests. In the general population, the risk of VTE IS estimated to be 0. . .
Patients with one episode of VTE have an increased nsk of recurrence. The risk of recurrence in unselccted patients after completion of a 3-month course of anticoagulant therapy is 17.5% in 2 yea~s. 24.6% i.n 5 y.ears and 30.Yk after 8 years." There is an increased fisk of r~currenc~when t.he thrombotic event is idiopathic and not III associauon with a recognized risk factor such as surgery or pregnancy.6.'.6t> In patients who have had two episodes of VTE. the recurrence rate after follow up for 4 years has been reported to be 20.7% in patients treated for 6 months with oral anticoagulation compared to 2.6q.. in those continued on treatment indefinitely (relative risk 8.0).67 Thus. prolonged oral anticoagulation decreases the recurrence rate of VTE. but this is associated with an increased risk of major hemorrhage (8.6 versus 2.7 C if ).
Management

Who should be tested?
Patients with unexplained episodes of VTE. particularly those under the age of 45 years. or those with recurrent thrombosis or thrombosis at unusual sites. are candidates for laboratory evaluation. Patients with an episode of VTE and family history of such events need to be evaluated. First degree family members of patients with a documented inherited abnormality should be evaluated. Patients should be evaluated to exclude acquired causes of VTE such as malignancy. myeloproliferative diseases. antiphospholipi.d antibodies. and lupus anticoagulants. There is little eVIdence at present to support screening of the general population for any of the inherited deficiencies in the natural anticoagulant mechanisms. What laboratory assays should be included?
The laboratory investigation should include the c1otti~g (functional) test for resistance to APC together WIth measurement of the plasma levels of Pc, PS and AT. An abnormal clotting test for resistance to APC needs to be confirmed by tests to establish the gene defect. Because many of the dysfibrinogenemias may be detected by an abnormal thrombin time. it may be worthwhile to include this test. With an increasing recognition of hyperhomocysteinemia as an important risk factor for venous thrombosis. measurement of plasma homocysteine levels should become a part of this work-up even though several acquired conditions clearly influence the levels.
The timing of obtaining the laboratory tests is of importance. Acute thrombotic episode and/or the therapy may affect plasma levels of some of the proteins of interest. Laboratory testing is best performed away from the time of the acute event, when the patient is not on treatment with anticoagulants. Heparin therapy induces a decline in AT levels.?"?" Warfarin lowers both PC and PS levels. During pregnancy and acute inflammato,?, co~ditions. I~vel~of free PS may be reduced because ot an Increase 111 CAb· binding protein levels. Moreover. conditions affect.ing ,the partial thromboplastin time (PTT) and rrothromb~n time (PT) will affect the clot-based assays of APe resistance. This is particularly relevant in patients on warfarin therapy. However. recently a modification of the original clotting test has been developed that involves performing the test on a dilution of a patient's plasma in factor V-deficient plasma. 9 . 70 This modification can overcome the li~itation with respect to samples from patients on warfann. The DNA-based test for the mutation is the definitive method to establish factor V Leiden,
Treatment
Therapeutic recommendations in patients with symptomatic and asymptomatic hypercoagulable states need to be based on estimates of risk of VTE. the efficacy of therapy in preventing the events, and the risks of therapy. Anticoagulation is clearly associated with a risk of hemorrhage and. in the ultimate analysis. a risk-benefit consideration is the determining factor regarding therapy. There is a ,need for additional information on all these aspects before fum guidelines can be evolved. In man~<~reas. I.ittle inf~nnati~n is available: in some areas the information available IS compromised because the diagnosis of VTE has not. al":ays been confirmed by objective tests. Thus, the guidelines described here are subject to modification as new data on risk-benefit analyses emerge and by the need to individualize therapy in certain subsets of patients. One example consists of otherwise healthy patients with a factor V Leiden who have sustained a single episode of VTE provoked by a high-risk surgical procedure. It m<~y be app.ropriate to consider them for short-term anticoagulation instead of indefinite long-term anticoagulant. On the other hand. anticoagulation is effective in decreasing the recurrence rate in these individuals."] Treatment of acute VTE events in patients with inherited deficiencies remains the same as in other patients. Patients with one or more episodes of VTE and a laboratory diagnosis of an inherited defect should be considered for indefinite anticoagulation."! Such patients have an enhanced rate of recurrence that is decreased by anticoagul-ation. [63] [64] [65] [66] [67] This recommendation is particularly relevant if the initial acute event was life-threatening (either in the individual or his family members), unprovoked or associated with a strong family history of VTE. Because not all patients with VTE can be shown to have a predisposing inherited mechanism by current laboratory tests, individuals with two or more VTE events that are idiopathic without a defined inherited abnormality should be treated with indefinite anticoagulation. This recommendation is strengthened if the events are life-threatening or at unusual sites (cerebral veins, mesenteric veins. inferior vena cava) and by the presence of a family history.
As of now, there is little convincing data to recommend indefinite anticoagulation in asymptomatic carriers of AT, PC, PS or factor V Leiden, These individuals are at an increased risk for VTE relative to normal subjects. There is a strong need to institute prophylactic measures (with' adjusted doses of heparin or oral anticoagulants) in these individuals during periods of increased risk such as surgery and immobilization. In the presence of a family history of fatal VTE, these individuals should be considered for indefinite anticoagulation."
Therapy of patients with hyperhomocysteinemia remains unclear. Homocystinuria secondary to CBS deficiency has been treated successfully in newborns by dietary methionine restriction. In addition, a substantial number of patients respond to large doses of vitamin B 6 when initiated early in the neonatal period.'? Severe homocysteinemia associated with MTHFR deficiency has proved to be less responsive to vitamin therapy but therapeutic experience is limited. Vitamin status is a major determinant of mild to moderate hyperhomocysteinemia and vitamin supplementation, particularly with folic acid. is effective in lowering mildly elevated levels of homocysteine, regardless of initial serum vitamin levels. 19.2lJ.7 I In view of their low cost and safety, a trial of vitamin supplementation in patients with hyperhomocysteinemia and thrombosis has been suggested but there is no information to date to support the overall clinical efficacy of such an approach. A compelling argument has been presented that increased intake of folic acid (including by fortification of grain) may have a substantial impact on cardiovascular disease." There is a paucity of information regarding the effectiveness of anticoagulant prophylaxis in hyperhomocysteinemia. Clinical trials are urgently needed to address these issues.
Management of women with hypercoagulable states
Oral contraceptives increase the risk of VTE by eightfold in women with factor V Leiden.":' It is generally accepted that oral contraceptives should not be administered to women with an inherited hypercoagulable state. The decision regarding estrogen replacement therapy in postmenopausal women is more complex. Because the estrogen dose is much less, estrogen replacement therapy has hitherto not been considered contraindicated in women with a hypercoagulable state." However, recent studies indicate a twofold to fourfold relative risk of venous thrombosis among perimenopausal and postmenopausal women on hormone replacement therapy.P:" These studies point to the need for a careful consideration of the indication for such therapy in individual patients and evaluation of existing risk factors for VTE. Given the other overall beneficial effects Vascular Medicine 1997; 2: 313-320 of estrogen replacement therapy on cardiovascular mortality. this issue is far from resolved.
There is increased fetal loss (particularly stillbirth) in women with inherited hypercoagulable states." Pregnancy should be considered as a high-risk situation in patients with hypercoagulable states, especially AT deficiency.":" There is an increased risk of postpartum VTE in patients with inherited protein deficiencies. Patients with a history of VTE should receive full dose anticoagulation with heparin throughout pregnancy. The indications for asymptomatic patients are less clear-cut. Asymptomatic patients with AT deficiency probably need to be considered as candidates for subcutaneous heparin therapy at lower doses during pregnancy. Therapy in asymptomatic patients with other deficiencies needs to be individualized.
Conclusion
A number of inherited abnormalities are currently recognized which predispose to VTE. However, in a substantial proportion (> 50%) of patients with a familial predisposition to VTE, none of these entities is detected, indicating the existence of other mechanisms. From a mechanism point of view, venous thrombosis needs to be considered as a multigene disorder where a number of discrete genetic factors interact in a complex manner to lead to the clinical events in individual patients.57.79.8o Moreover, the interaction of acquired factors and genetic abnormalities is highly relevant and needs to be considered. The evidence for such interactions is rapidly accumulating in the form of co-segregation of multiple genetic abnormalities, such as. for example, factor V Leiden and protein C or S deficiency.Y'" Further studies should clarify these and other interactions and provide better insights into the predisposing mechanisms in individual patients who show a remarkable heterogeneity with respect to clinical events, even among family members. From the perspective of management, current therapeutic recommendations are based on information that is far from complete. Further clinical trials are needed to develop evidence-based guidelines for many of the clinical scenarios that are commonly encountered.
